Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company (NYSE: CC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its operations as a global chemistry company. Through its Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials businesses, Chemours reports segment performance, risk factors, capital structure, and environmental and legal matters in its periodic reports. On this CC filings page, investors can review those regulatory disclosures alongside AI-generated summaries that help explain key points in accessible language.
Chemours’ quarterly and annual reports discuss net sales and profitability across Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, including trends in Opteon™ and Freon™ refrigerants, Ti-Pure™ titanium dioxide pigments, and advanced materials associated with brands such as Nafion™, Teflon™, Viton™, and Krytox™. These filings also describe the company’s global footprint, its customer and manufacturing base, and strategic priorities such as the Pathway to Thrive framework.
Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, receivables purchase arrangements, environmental settlements such as the proposed judicial consent order with the State of New Jersey related to PFAS and other environmental claims, adoption of executive severance policies, and changes in board leadership. Securities registration information confirms that Chemours’ common stock trades on the New York Stock Exchange under the symbol CC.
On Stock Titan, Chemours SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight important disclosures, segment commentary, and notable legal or financing developments. Users can quickly scan lengthy reports, identify items related to environmental matters, capital structure, or governance, and then drill into the original documents for full detail. This page is a resource for reviewing Chemours’ regulatory history, understanding how its three main businesses are performing, and tracking significant corporate events as they are reported to the SEC.
MATHER COURTNEY reported acquisition or exercise transactions in this Form 4 filing.
Chemours director Courtney Mather received a routine equity grant in the form of deferred stock units. On this Form 4, Mather was awarded 1,305 deferred stock units at an indicated value of $22.03 per unit, each equivalent to one share of Chemours common stock.
The deferred stock units, including associated dividend equivalent units, will become payable in the first month after Mather’s termination of service as a director. Following this grant, Mather holds a total of 7,552.3528 deferred stock units, representing deferred, not currently exercisable, equity-based compensation.
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.
The Chemours Company completed a private Offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034. The notes were sold to qualified institutional buyers and are senior unsecured obligations guaranteed by a subsidiary.
Chemours used the net proceeds, together with cash on hand, to redeem $188,000,000 of 5.750% senior notes due 2028 for an aggregate redemption price of about $189,800,000 plus interest. The remaining net proceeds are expected to fund the redemption of 5.375% senior notes due 2027 for an aggregate redemption price of about $500,300,000, plus accrued interest.
The Chemours Company is asking shareholders to elect eleven directors and approve several governance and compensation proposals at its virtual 2026 annual meeting on April 24, 2026. Items include director elections, an advisory vote on executive pay, a new 2026 Equity and Incentive Plan, and auditor ratification.
The proxy highlights Chemours’ Pathway to Thrive strategy, focused on operational excellence, growth in areas like semiconductors and data centers, portfolio simplification, and long-term risk reduction. In 2025, the company delivered $5.8 billion in net sales, $742 million in Adjusted EBITDA and returned $78 million in dividends, while recording a net loss of $386 million largely due to litigation-related charges.
Board oversight features an independent chair, lead independent director, fully independent committees and strong risk, cybersecurity and sustainability governance. Since 2018, Chemours reports a 76% reduction in fluorinated organic chemical process emissions and a 52% cut in Scope 1 and 2 greenhouse gas emissions, supporting its Trusted Chemistry and 2030 responsibility goals.
Chemours senior vice president Kristine M. Wellman reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 25,708 restricted stock units, which are scheduled to vest in three equal annual installments beginning on March 1, 2027. To cover tax obligations from previously vesting RSUs and dividend equivalent units, 3,359 shares were automatically withheld at a price of $18.24 per share, and the disclosure states that no shares were sold in the market. After these changes, she reports direct ownership of 73,750.6057 shares, RSUs, and dividend equivalent units in total.
Chemours executive Gerardo Familiar Calderon reported equity compensation changes involving company common stock. He received a grant of 25,708 shares of common stock at a price of $0.0000 per share as a grant, award, or other acquisition, structured as restricted stock units and related dividend equivalent units.
Separately, 2,635 shares were automatically withheld at $18.24 per share to satisfy tax obligations upon vesting of existing restricted stock units; footnotes state that no shares were sold and the transaction is exempt under Rule 16b-3. The new RSU award is scheduled to vest in three equal annual installments beginning on March 1, 2027, and the reported holdings include directly owned shares, RSUs, and dividend equivalent units.
Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.
Chemours Co reported that officer Michael Robert Foley acquired two grants of common stock in the form of restricted stock units. One award covers 25,013 RSUs that vest in three equal annual installments beginning on March 1, 2027, and another covers 50,027 RSUs scheduled to vest on March 1, 2029. Following these awards, Foley directly holds or is credited with 78,540 Chemours equity units, including directly owned shares, RSUs and related dividend equivalent units.
Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.